General News

Professor Mike Jewett We are honored and delighted to welcome synthetic biology leader Professor Michael Jewett to our Scientific Advisory Board. Professor Jewett brings Nuclera subject matter expertise on harnessing cell- free protein synthesis technologies. His research into this technology spans various research areas including in vitro glycosylation, ribosome engineering, and cell-free diagnostics. “The prestigious…

One Vision Park Nuclera is proud to announce that it has found a new home for its global headquarters working in partnership with Lateral, a UK-based real estate investment firm. The new office will consolidate three existing Nuclera facilities on the Cambridge Science Park into a single 30,000 sq ft location on the Vision Park.…

Nuclera’s eProtein™ bioprinter will make proteins accessible to scientists CAMBRIDGE, UK (02 Feb 2022) – Nuclera, a biotech company developing cutting-edge benchtop protein printing technologies, today announced that the first close of its Series B financing has raised $42.5 million. The funds raised will be used to accelerate the development and commercialization of its eProtein™ desktop…

We are excited to be one of the companies chosen to be part of Edison Open House: Global Healthcare – 2021, organised by the Edison Group, London Stock Exchange Group (LSEG) and Taylor Wessing. This event highlights leading innovators working on the most important advances of 2021 for the global healthcare and life science industries. Watch here as our…

We are pleased to announce that Dr Joe Keegan joined our Board as Non-executive Director. Dr Keegan has more than 30 years of experience in life science businesses. He was CEO at ForteBio Inc, a life science tool company, from 2007 to 2012 when it was sold to Pall Corporation. While at the helm he…

Nuclera desktop bioprinter powered by digital microfluidic technology We are proud to announce that we have acquired E Ink’s digital microfluidics unit to form our US subsidiary. Combining the technologies of the two companies will enable the delivery of a revolutionary desktop protein and gene “bioprinter” with breakthrough speed and convenience for researchers in human…

We are proud to share the news that Nuclera has been working with the University of Southampton to characterise ACE2, the main entry point of the SARS-CoV-2 coronavirus. Nuclera’s protein scientist Dr Stephanie Reikine’s collaborative work with the teams at Southampton has resulted in a peer-reviewed publication in the Feb 2020 issue of Nature Genetics.…